[Current status of surgical treatment of peritoneal metastases from colorectal cancer].
Aktueller Stand der chirurgischen Therapie peritonealer Metastasen bei kolorektalen Karzinomen.
Cytoreductive surgery
Hyperthermic intraperitoneal chemotherapy
Oxaliplatin
PRODIGE7
Peritonectomy
Journal
Chirurgie (Heidelberg, Germany)
ISSN: 2731-698X
Titre abrégé: Chirurgie (Heidelb)
Pays: Germany
ID NLM: 9918383081906676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
18
07
2022
pubmed:
21
8
2022
medline:
3
12
2022
entrez:
20
8
2022
Statut:
ppublish
Résumé
Cytoreductive surgery, often in combination with hyperthermic intraperitoneal chemotherapy (HIPEC), has been instrumental in improving the survival of patients with peritoneal metastases from colorectal cancer. Recent studies have highlighted the benefits of complete cytoreduction, while the role of the HIPEC treatment remains unclear. An oxaliplatin-based HIPEC over 30 min could not achieve any clear benefits in studies on colorectal cancer, neither in the therapeutic nor in the prophylactic setting, but caused relevant side effects and increased the morbidity. The negative results of these studies with respect to oxaliplatin-based HIPEC require critical appraisal; however, they should by no means be regarded as a general setback for surgical treatment of peritoneal metastases and be misunderstood as a general failure of this treatment. While HIPEC after complete surgical cytoreduction of peritoneal metastases from colorectal cancer requires further research, cytoreductive surgery should still be regarded as a highly effective treatment for suitable patients with limited abdominal tumor dissemination. Die zytoreduktive Chirurgie, vielfach in Kombination mit einer hyperthermen intraperitonealen Chemotherapie (HIPEC), hat maßgeblich zur Verbesserung des Überlebens von Patientinnen und Patienten mit peritonealen Metastasen kolorektaler Karzinome beigetragen. Während für den Nutzen einer vollständigen Zytoreduktion klare Belege existieren, ist der Stellenwert der HIPEC-Behandlung ungeklärt. Eine Oxaliplatin-haltige HIPEC über 30 min war in Studien bei kolorektalen Karzinomen weder in therapeutischer noch in prophylaktischer Indikation klar von Vorteil, verursachte aber relevante Nebenwirkungen und steigerte die Morbidität. Die negativen Ergebnisse dieser Studien in Bezug auf die Oxaliplatin-haltige HIPEC erfordern eine kritische Betrachtung. Sie dürfen aber keinesfalls als allgemeiner Rückschlag für die chirurgische Therapie peritonealer Metastasen missverstanden werden. Während die HIPEC nach einer kompletten chirurgischen Zytoreduktion peritonealer Metastasen kolorektaler Karzinome weiterer Erforschung bedarf, kann die zytoreduktive Chirurgie als hocheffektive Therapie für geeignete Patienten mit einer begrenzten abdominellen Tumoraussaat gelten.
Autres résumés
Type: Publisher
(ger)
Die zytoreduktive Chirurgie, vielfach in Kombination mit einer hyperthermen intraperitonealen Chemotherapie (HIPEC), hat maßgeblich zur Verbesserung des Überlebens von Patientinnen und Patienten mit peritonealen Metastasen kolorektaler Karzinome beigetragen. Während für den Nutzen einer vollständigen Zytoreduktion klare Belege existieren, ist der Stellenwert der HIPEC-Behandlung ungeklärt. Eine Oxaliplatin-haltige HIPEC über 30 min war in Studien bei kolorektalen Karzinomen weder in therapeutischer noch in prophylaktischer Indikation klar von Vorteil, verursachte aber relevante Nebenwirkungen und steigerte die Morbidität. Die negativen Ergebnisse dieser Studien in Bezug auf die Oxaliplatin-haltige HIPEC erfordern eine kritische Betrachtung. Sie dürfen aber keinesfalls als allgemeiner Rückschlag für die chirurgische Therapie peritonealer Metastasen missverstanden werden. Während die HIPEC nach einer kompletten chirurgischen Zytoreduktion peritonealer Metastasen kolorektaler Karzinome weiterer Erforschung bedarf, kann die zytoreduktive Chirurgie als hocheffektive Therapie für geeignete Patienten mit einer begrenzten abdominellen Tumoraussaat gelten.
Identifiants
pubmed: 35987785
doi: 10.1007/s00104-022-01694-9
pii: 10.1007/s00104-022-01694-9
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
1126-1132Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Baratti D, Kusamura S, Azmi N et al (2020) Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C‑based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol 27:98–106
doi: 10.1245/s10434-019-07935-2
pubmed: 31691116
Cashin P, Sugarbaker PH (2021) Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J Gastrointest Oncol 12:S120–S128
doi: 10.21037/jgo-2020-05
pubmed: 33968432
pmcid: 8100699
Driel WJ van, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240
doi: 10.1056/NEJMoa1708618
pubmed: 29342393
Franko J, Ibrahim Z, Gusani NJ et al (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756–3762
doi: 10.1002/cncr.25116
pubmed: 20564081
Franko J, Shi Q, Goldman CD et al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–267
doi: 10.1200/JCO.2011.37.1039
pubmed: 22162570
Glockzin G, Ghali N, Lang SA et al (2009) Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. J Surg Oncol 100:306–310
doi: 10.1002/jso.21332
pubmed: 19697436
Goere D, Glehen O, Quenet F et al (2018) Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-NTC01226394). J Clin Oncol 36(15_suppl):3531
doi: 10.1200/JCO.2018.36.15_suppl.3531
Goere D, Souadka A, Faron M et al (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964
doi: 10.1245/s10434-015-4387-5
pubmed: 25631064
Horvath P, Yurttas C, Beckert S et al (2021) Twelve-year single center experience shows safe implementation of developed peritoneal surface malignancy treatment protocols for gastrointestinal and gynecological primary tumors. Cancers (Basel) 13(10):2471
doi: 10.3390/cancers13102471
pubmed: 34069475
Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53–63
doi: 10.1007/978-1-4613-1247-5_4
pubmed: 8849943
Klaver CEL, Wisselink DD, Punt CJA et al (2019) Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 4:761–770
doi: 10.1016/S2468-1253(19)30239-0
pubmed: 31371228
Kuijpers AM, Aalbers AG, Nienhuijs SW et al (2015) Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg 39:453–460
doi: 10.1007/s00268-014-2801-y
pubmed: 25245434
Kuijpers AM, Hauptmann M, Aalbers AG et al (2016) Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed. Eur J Surg Oncol 42:244–250
doi: 10.1016/j.ejso.2015.08.162
pubmed: 26375923
Pameijer CR (2022) HIPEC Trials and the US: A Review and Call to Action Ann Surg Oncol 29(2):866–872. https://doi.org/10.1245/s10434-021-10769-6
doi: 10.1245/s10434-021-10769-6
pubmed: 34599434
Pereira F, Serrano A, Manzanedo I et al (2022) GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin‑C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer 22:536
doi: 10.1186/s12885-022-09572-7
pubmed: 35549912
pmcid: 9097342
Quénet F, Elias D, Roca L et al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):256–266
doi: 10.1016/S1470-2045(20)30599-4
pubmed: 33476595
Repullo DJ, Barbois S, Leonard D et al (2021) The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective analysis. Eur J Surg Oncol 47:1661–1667
doi: 10.1016/j.ejso.2021.01.018
pubmed: 33602530
Robert Koch-Institut (2021) Krebs in Deutschland für 2017/2018. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2021/krebs_in_deutschland_2021.pdf?__blob=publicationFile . Zugegriffen: 27. Mai 2022
Rovers KP, Bakkers C, Simkens G et al (2019) Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II–III, randomised, superiority study (CAIRO6). BMC Cancer 19:390
doi: 10.1186/s12885-019-5545-0
pubmed: 31023318
pmcid: 6485075
Rovers KP, Bakkers C, Erning FN van et al (2020) Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases. JAMA Oncol 6:e202701
doi: 10.1001/jamaoncol.2020.2701
pubmed: 32672798
pmcid: 7366283
Rovers KP, Kok NFM, Punt CJA et al (2021) Limitations of the PRODIGE 7 trial. Lancet Oncol 22:e174
doi: 10.1016/S1470-2045(21)00063-2
pubmed: 33932372
Schneider MA, Eshmuminov D, Lehmann K (2017) Major postoperative complications are a risk factor for impaired survival after CRS/HIPEC. Ann Surg Oncol 24:2224–2232
doi: 10.1245/s10434-017-5821-7
pubmed: 28265776
Schneider MA, Eden J, Pache B et al (2018) Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 268:845–853
doi: 10.1097/SLA.0000000000002899
pubmed: 30303876
Segelman J, Granath F, Holm T et al (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705
doi: 10.1002/bjs.8679
pubmed: 22287157
Seyfried N, Yurttas C, Burkard M et al (2022) Prolonged exposure to oxaliplatin during HIPEC improves effectiveness in a preclinical micrometastasis model. Cancers (Basel) 14(5):1158
doi: 10.3390/cancers14051158
pubmed: 35267468
pmcid: 8909393
Simkens GA, Oudheusden TR van, Luyer MD et al (2015) Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol 22:2656–2662
doi: 10.1245/s10434-014-4297-y
pubmed: 25515200
Simkens GA, Rovers KP, Nienhuijs SW et al (2017) Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res 9:259–266
doi: 10.2147/CMAR.S119569
pubmed: 28721098
pmcid: 5501638
Turaga K, Levine E, Barone R et al (2014) Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 21:1501–1505
doi: 10.1245/s10434-013-3061-z
pubmed: 23793364
Ubink I, Bolhaqueiro ACF, Elias SG et al (2019) Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg 106:1404–1414
doi: 10.1002/bjs.11206
pubmed: 31197820
pmcid: 6771632
Verwaal VJ, Bruin S, Boot H et al (2008) 8‑year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432
doi: 10.1245/s10434-008-9966-2
pubmed: 18521686
Verwaal VJ, Ruth S van, Bree E de et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743
doi: 10.1200/JCO.2003.04.187
pubmed: 14551293
Vlasakker VCJ van de, Lurvink RJ, Cashin PH et al (2021) The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 47:2888–2892
doi: 10.1016/j.ejso.2021.05.023
pubmed: 34020808
Waite K, Youssef H (2017) The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol 24:705–720
doi: 10.1245/s10434-016-5712-3
pubmed: 28058545
Yurttas C, Hoffmann G, Tolios A et al (2018) Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med 7(12):567
doi: 10.3390/jcm7120567
pubmed: 30572653
pmcid: 6306814